OraPharma, Inc. (Nasdaq: OPHM - news) announced that Sven Glindemann, DMD, of Harvard School of Dental Medicine, Department of Periodontology, presented data from a preclinical study of OraPharma's compound OC-1016 for bone regeneration at the American Academy of Periodontology, Orban Competition, in Philadelphia.
Results of this study showed that dental implants treated with OC-1016 showed statistically greater osseointegration (bone growth), as measured by bone to implant contact area and bone density, than untreated implants in a preclinical model after four weeks. OC-1016 is a synthetic peptide based on the protein osteopontin.
``These data are very encouraging and will support our filing with the U.S. Food and Drug Administration to begin human clinical studies,'' said Michael D. Kishbauch, President and Chief Executive Officer of OraPharma. ``Our development pipeline is broadening in focus and this achievement builds importantly on our existing technology base. OC-1016 not only expands our scope within the periodontal market, but may provide opportunities in other areas of bone regeneration, such as orthopedics.''
